A case of uremic pruritus and papulo-pustular rash associated with anti-EGFR therapy in a patient with rectal cancer and chronic kidney disease

Abstract

Uremic pruritus is a common symptom in chronic kidney disease and end-stage renal failure. In addition to physical discomfort uremic pruritus disrupts sleep, negatively affects the psycho-emotional state and quality of life. In this group of patients, the association of uremic pruritus with an increase in mortality due to any causes was demonstrated. At the same time, there are no standardized approaches to the treatment of uremic itching. There is also a special category of patients receiving antitumor therapy and developing dermatological adverse events, also potentially accompanied by itching.

This article presents a case of uremic pruritus in a patient with papulo-pustular cutaneous reaction (grade II on a Scale Common Terminology Criteria for Adverse Events, CTCAE v 5.0) to the epidermal growth factor (EGFR) inhibitor cetuximab in combination with leucovorin and 5-fluorouracil for rectal cancer. Treatment of uremic pruritus with small doses of gebapentin (300 mg/day) led to complete regression of pruritus. Papulo-pustular rashes completely regressed after recommended systemic and topical therapy according to the severity of rush (doxycycline 100 mg 2 times a day for 5 days, cream with neomycin, natamycin and hydrocortisone 3 times a day for 7 days). Pruritus was absent during the next 6 months of follow-up. Antitumor therapy was not interrupted due to acneiform rush, and following supportive topical therapy allowed to control severity of exacerbations which did not exceed I–II grade according to CTCAE v 5.0 and did not require the addition of systemic therapy.

Thus, therapy of uremic pruritus with gabapentin has shown was effective also in a patient with severe comorbid pathology. Supportive topical therapy consistent with the severity of papulo-pustular rash reduced the severity of exacerbations during following EGFR inhibitor therapy.

Keywords

chronic kidney disease / pruritus / uremic pruritus / papulo-pustular rashes / gabapentin / cetuximab / case report

References

[1] Kim D, Pollock C. Epidemiology and burden of chronic kidney disease-associated pruritus. Clin Kidney J. 2021;14(Suppl 3):i1–i7. doi: 10.1093/ckj/sfab142

[2] Kim D., Pollock C. Epidemiology and burden of chronic kidney disease-associated pruritus // Clin Kidney J. 2021. Vol. 14, Suppl. 3. Р. i1–i7. doi: 10.1093/ckj/sfab142

[3] Lugon JR. Uremic pruritus: A review. Hemodial Int. 2005;9(2):180–188. doi: 10.1111/j.1492-7535.2005.01130.x

[4] Lugon J.R. Uremic pruritus: A review // Hemodial Int. 2005. Vol. 9, N 2. Р. 180–188. doi: 10.1111/j.1492-7535.2005.01130.x

[5] Urbonas A, Schwartz RA, Szepietowski JC. Uremic pruritus: An update. Am J Nephrol. 2001;21(5):343–350. doi: 10.1159/000046272

[6] Urbonas A., Schwartz R.A., Szepietowski J.C. Uremic pruritus: An update // Am J Nephrol. 2001. Vol. 21, N 5. Р. 343–350. doi: 10.1159/000046272

[7] Volkov MM, Dobronravov BA. Uremic itching in patients on renal replacement therapy (program of continuous postgraduate education in nephrology). Nephrology. 2006;10(2):110–117. (In Russ).

[8] Волков М.М., Добронравов B.A. Уремический зуд у больных на заместительной почечной терапии (программа непрерывного последипломного образования по нефрологии) // Нефрология. 2006. Т. 10, № 2. С. 110–117.

[9] Mettang T. Uremic itch management. Curr Probl Dermatol. 2016;(50):133–141. doi: 10.1159/000446056

[10] Mettang T. Uremic itch management // Curr Probl Dermatol. 2016. N 50. Р. 133–141. doi: 10.1159/000446056

[11] Lau T, Leung S, Lau W. Gabapentin for uremic pruritus in hemodialysis patients: A qualitative systematic review. Can J Kidney Health Dis. 2016;(3):14. doi: 10.1186/s40697-016-0107-8

[12] Lau T., Leung S., Lau W. Gabapentin for uremic pruritus in hemodialysis patients: A qualitative systematic review // Can J Kidney Health Dis. 2016. N 3. Р. 14. doi: 10.1186/s40697-016-0107-8

[13] Weisshaar E, Matterne U, Mettang T. How do nephrologists in haemodialysis units consider the symptom of itch? Results of a survey in Germany. Nephrol Dial Transplant. 2009;24(4):1328–1330. doi: 10.1093/ndt/gfn769

[14] Weisshaar E., Matterne U., Mettang T. How do nephrologists in haemodialysis units consider the symptom of itch? Results of a survey in Germany // Nephrol Dial Transplant. 2009. Vol. 24, N 4. Р. 1328–1330. doi: 10.1093/ndt/gfn769

[15] Simonsen E, Komenda P, Lerner B, et al. Treatment of uremic pruritus: A systematic review. Am J Kidney Dis. 2017;70(5):638–655. doi: 10.1053/j.ajkd.2017.05.018

[16] Simonsen E., Komenda P., Lerner B., et al. Treatment of uremic pruritus: A systematic review // Am J Kidney Dis. 2017. Vol. 70, N 5. Р. 638–655. doi: 10.1053/j.ajkd.2017.05.018

[17] Koroleva IA, Bolotina LV, Gladkov OA, et al. Practical recommendations for the drug treatment of dermatological reactions in patients receiving antitumor drug therapy. Malignant tumors. 2022;12(3S2-2):101–122. (In Russ). doi: 10.18027/2224-5057-2022-12-3s2-101-122

[18] Королева И.А., Болотина Л.В., Гладков О.А., и др. Практические рекомендации по лекарственному лечению дерматологических реакций у пациентов, получающих противоопухолевую лекарственную терапию // Злокачественные опухоли. 2022. Т. 12, № 3S2-2. С. 101–122. doi: 10.18027/2224-5057-2022-12-3s2-101-122

[19] Lacouture ME, Sibaud V, Gerber PA, et al.; ESMO Guidelines Committee. Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines. Ann Oncol. 2021;32(2):157–170. doi: 10.1016/j.annonc.2020.11.005

[20] Lacouture M.E., Sibaud V., Gerber P.A., et al.; ESMO Guidelines Committee. Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines // Ann Oncol. 2021. Vol. 32, N 2. Р. 157–170. doi: 10.1016/j.annonc.2020.11.005

[21] Shatokhina EA, Kruglova LS, Polonskaya AS, Nosikova PG. Acne-like rash: A dermatological undesirable phenomenon of therapy with monoclonal antibodies to EGFR. Pharmateca. 2020;27(8):56–60. (In Russ). doi: 10.18565/pharmateca.2020.8.56-60

[22] Шатохина Е.А., Круглова Л.С., Полонская А.С., Носикова П.Г. Акнеподобная сыпь ― дерматологическое нежелательное явление терапии моноклональными антителами к EGFR // Фарматека. 2020. Т. 27, № 8. С. 56–60. doi: 10.18565/pharmateca.2020.8.56-60

[23] Shatokhina EA, Kruglova LS, Polonskaya AS. Treatment of acne-like rash induced by monoclonal antibodies to the epidermal growth factor receptor (EGFR). Medical Council. 2020;(20):157–164. doi: 10.21518/2079-701X-2020-20-157-164

[24] Шатохина Е.А., Круглова Л.С., Полонская А.С. Лечение акнеподобной сыпи, индуцированной моноклональными антителами к рецептору эпидермального фактора роста (EGFR) // Медицинский совет. 2020. № 20. С. 157–164. doi: 10.21518/2079-701X-2020-20-157-164

RIGHTS & PERMISSIONS

Michenko A.V., Kruglova L.S., Shatokhina E.A., Lvov A.N., Simenskaya E.M., Romanov D.V., Kononenko I.B., Snegovoy A.V.